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MaGlucagon-like peptide-1-(7-36) amide (GLP-1) is a human incretin hormone responsible for the release of insulin in response
to food. Pre-clinical and human physiological studies have demonstrated cardioprotection from ischemia-reperfusion injury.
It can reduce infarct size, ischemic left ventricular dysfunction, and myocardial stunning. GLP-1 receptor agonists have also
been shown to reduce infarct size in myocardial infarction. The mechanism through which this protection occurs is uncertain
but may include hijacking the subcellular pathways of ischemic preconditioning, modulation of myocardial metabolism, and
hemodynamic effects including peripheral, pulmonary, and coronary vasodilatation. This review will assess the evidence for
each of these mechanisms in turn. Challenges remain in successfully translating cardioprotective interventions from bench-
to-bedside. The window of cardioprotection is short and timing of cardioprotection in the appropriate clinical setting is
critically important. We will emphasize the need for high-quality, well-designed research to evaluate GLP-1 as a cardio-
protective agent for use in real-world practice. (J Am Coll Cardiol Basic Trans Science 2016;1:267–76) ©2016 The Authors.
Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).I schemic heart disease is the most importantcause of morbidity and mortality in the devel-oped world. Recent advances in revasculariza-
tion of coronary arteries through percutaneous
coronary intervention (PCI) and coronary artery
bypass grafting have had a dramatic improvement in
the fate of patients suffering with ischemic heart dis-
ease (1). Nonetheless, revascularization does not
address damage from ischemia-reperfusion (IR)
injury and indeed may even contribute to it. For
example, up to ﬁfty percent of the ﬁnal infarct size
of an acute myocardial infarction is attributable to
IR injury (2). Additionally, IR injury is responsible
for nonlethal effects, for example, myocardial stun-
ning, arrhythmia and late remodeling. Therapies
that reduce these detrimental effects of IR injury are
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use a number of substrates for the generation of the
adenosine triphosphate (ATP), required to power
myocardial work. Glucose is the most efﬁcient
generator of ATP per unit of oxygen available (3).
Therapies that increase glucose oxidation in prefer-
ence to free fatty acids could reduce the impact of
myocardial ischemia.
Glucagon-like peptide-1-(7-36) amide (GLP-1) is a
human incretin hormone produced by the gut in
response to food. It is primarily an insulinotropic
hormone and has been extensively studied as a novel
treatment for type 2 diabetes mellitus. It acts in a
glucose-dependent manner, thus reducing the risk of
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ABBR EV I A T I ON S
AND ACRONYMS
ATP = adenosine triphosphate
ANP = atrial natriuretic peptide
AMI = acute myocardial
infarction
DPP = dipeptidyl-peptidase
GLP-1 = glucagon-like peptide
1-(7-36) amide
GLP-1R = GLP-1 receptor
GLP-1RA = GLP-1 receptor
agonist
IC = ischemic conditioning
IR = ischemia reperfusion
PCI = percutaneous coronary
intervention
RISK = reperfusion injury
survival kinase
SAFE = survivor-activating
factor enhancement
STEMI = ST-segment elevation
myocardial infarction
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268hypoglycemic agents, GLP-1 has other
potentially beneﬁcial “off-target” cardiovas-
cular properties including optimization of
myocardial metabolism and possibly direct
cardioprotection through binding to a cardiac
receptor and signaling protection via sub-
cellular ischemic conditioning pathways.
GLP-1 STRUCTURE AND FUNCTION
GLP-1-(7-36) amide is a 30-amino acid cleav-
age product of pro-glucagon secreted by
enteroendocrine L-cells in the gut (4). Oral
ingestion of a meal is the primary physio-
logical stimulus to GLP-1 secretion (5). GLP-1
is not secreted in response to an intravenous
glucose infusion.
GLP-1 has receptor-dependent and -inde-
pendent actions. It causes glucose-
dependent insulin release through binding
the GLP-1 receptor (GLP-1R) on pancreatic
beta cells. GLP-1 does not cause hypoglyce-mia as its insulinotropic effect does not occur at a
blood glucose concentrations <70 mg/dl (6). GLP-1
has a number of other physiological effects which
serve to lower plasma glucose levels. These include
stimulation of insulin gene transcription in the beta
cell (7) and reduced gastric emptying (8). Enhance-
ment of peripheral insulin sensitivity remain un-
proven with conﬂicting evidence (9).
The GLP-1R is a 463-amino acid, G protein-coupled
receptor found on the cell surface membrane of
numerous tissues throughout the body. Its presence
within the myocardium has remained controversial.
Both mouse and primate studies have suggested that
GLP-1R remains conﬁned to the atria and possibly
just the sinoatrial node (10,11). The location of the
receptor is important in elucidating the mechanism
of GLP-1 cardioprotection. Evidence of receptor-
independent effects suggest that there may be an
alternative receptor or perhaps actions that do not
require a receptor (12,13), discussed further below.
GLP-1 is cleaved by the enzyme dipeptidyl pepti-
dase (DPP)-4 to GLP-1-(9-36) amide with a half-life of
approximately 2 min (14). The biological role of this
breakdown product is uncertain but it has reduced
incretin activity. GLP-1 is further degraded by neutral
endopeptidase to GLP-1 fragments whose biological
activity is the subject of ongoing research.
A number of pharmaceutical products have been
developed to use the incretin effect of GLP-1 while
avoiding the difﬁculties associated with its rapid
breakdown to an apparently inactive form. These
drugs include DPP-4 inhibitors such as sitagliptin(Januvia, Merck, Kenilworth, New Jersey), sax-
agliptin (Onglyza, AstraZeneca, Macclesﬁeld, United
Kingdom), and vildagliptin (Galvus, Novartis, Basel,
Switzerland), all of which increase levels of native
GLP-1; and DPP-4-resistant GLP-1 receptor agonists
(GLP-1RA) such as exenatide (Byetta, AstraZeneca,
United Kingdom) and liraglutide (Victoza, Novo
Nordisk, Bagsvaerd, Denmark).
PRE-CLINICAL EVIDENCE OF
GLP-1 CARDIOPROTECTION
GLP-1 protects cardiomyocytes from cell death.
In vitro, GLP-1 has been shown to avert cell death in
HL-1 murine adult cardiomyocytes treated with the
pro-apoptotic agent staurosporine (15). Both wild-
type and GLP-1R homozygous knockout mice experi-
enced cardioprotection from GLP-1-(7-36) and -(9-36),
suggesting the protective effect occurred indepen-
dent of receptor binding (16). GLP-1 protection was
similarly associated with reduced activation of pro-
apoptotic molecules in rats, and occurred regardless
of whether it was given prior to ischemia or in early
reperfusion (17,18). In vivo, GLP-1 infusion given to
dogs with pacing-induced cardiomyopathy improved
left ventricular function with systemic changes such
as reduced heart rate and blood pressure (19).
Furthermore, GLP-1 infusion reduced infarct size af-
ter IR injury (20).
GLP-1 RAs have also been shown to protect against
IR injury. Both albiglutide (Eperzan, GlaxoSmith-
Kline, Stevenage Herts, United Kingdom) and lix-
isenatide (Lyxumia, Sanoﬁ, Paris, France) reduced
ﬁnal infarct size in rat models (21,22), and pretreat-
ment with liraglutide protects in mice (23). In a
porcine model of IR injury, treatment with exenatide
for 3 days reduced infarct size and improved left
ventricular function (24). However, initiation of
exenatide after onset of ischemia did not result in
cardioprotection, suggesting that, at least for GLP-
1RAs, there may be a time-dependent element to the
cardioprotection (25).
MECHANISM OF GLP-1-MEDIATED
CARDIOPROTECTION
Many of the studies cited above have demonstrated
aspects of cardioprotection that provide clues to how
GLP-1 protects against IR injury. Several mechanisms
have been proposed for GLP-1-mediated car-
dioprotection. A change in myocardial glucose utili-
zation may result in increased metabolic efﬁciency
and myocardial resistance to ischemia, thus limiting
infarction. Vasodilation and reduction in systemic
and/or pulmonary vascular resistance can also reduce
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269cardiac work and ATP demand during ischemia.
Finally, the pathways of ischemic preconditioning
may be activated to increase cellular resistance to IR
injury. These pathways may overlap, limiting lethal
and nonlethal IR injury to various extents. Figure 1
offers an overview of a number of proposed mecha-
nisms for GLP-1-mediated cardioprotection. Evidence
for these mechanisms is reviewed below.
MYOCARDIAL GLUCOSE UTILIZATION. A change in
myocardial glucose utilization is consistent with the
physiological role of an incretin hormone. Fatty acids
are the main fuel for energy production in the heart
(26), although the omnivorous myocyte will use a
number of different sources for ATP production (3).
Glucose is the most oxygen-efﬁcient source of ATP
and is the preferred substrate when insulin and
glucose levels are high, as in the post-prandial state
(27). Glucose is preferentially metabolized in ischemic
tissues and this is facilitated by augmentation of
glucose uptake through up-regulation of the glucose
transporters GLUT1 and GLUT4 to the cell surface
membrane (28). Ischemic myocardium relies increas-
ingly on anaerobic respiration through glycolysis, and
if ischemia is prolonged intracellular levels of lactate
and Ca2þ rise, the pH falls, and ultimately initiates theFIGURE 1 Possible Mechanism of GLP-1-Mediated Cardioprotection:
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ever, these beneﬁts may have been mitigated by
clinical problems including risks of hypoglycemia and
hyperkalemia. Lack of a clear cardioprotective beneﬁt
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270(34). Additionally, albiglutide produced an increase in
myocardial glucose uptake and a shift from fatty acid
to carbohydrate oxidation during IR injury in rats (21).
In an ex vivo rat model, chronic treatment with DPP-4
inhibitors reduced infarct size in a glucose-dependent
manner (35).
A recent study in rats showed that GLP-1 appeared
to induce a switch to carbohydrate oxidation in the
area not at risk following IR injury, as well as an in-
crease in anaerobic glycolysis in the area subjected to
IR injury (36). An increase in glucose utilization in the
area not at risk may allow increased overall contrac-
tility of the ventricle during ischemia. Additionally, a
rise in glycolysis may represent an increased number
of viable cardiomyocytes in the ischemic area.
Conversely, a number of recent human studies
have cast doubt on changes in myocardial glucose
utilization as the mechanism behind GLP-1-mediated
cardioprotection. A study of 20 nondiabetic patients
given a 48-h subcutaneous infusion of GLP-1 did not
show any signiﬁcant change in metabolic parameters
(37). Furthermore, coronary sinus sampling in
humans subjected to brief coronary artery occlusion
demonstrated no signiﬁcant change in myocardial
glucose extraction when GLP-1 was infused (38). In
healthy volunteers, GLP-1 did not affect overall
myocardial glucose utilization in either normo- or
hypoglycemic states. The subgroup of volunteers
with a high baseline level of glucose utilization had a
reduced level in response to GLP-1. In contrast, those
with low baseline level were found to exhibit
increased glucose utilization (39).
Subtle changes in metabolism may have profound
effects on the cardiomyocyte in IR injury but remain
difﬁcult to detect in human studies. Careful design of
human studies is needed to untangle the metabolic
changes induced by GLP-1 and those responsible for
cardioprotection.
CONDITIONING PATHWAYS. Ischemic conditioning
(IC) is the resistance of tissue to prolonged ischemia,
induced by repeated cycles of transient ischemia and
reperfusion, either locally or in a remote tissue. It has
been demonstrated to be beneﬁcial in both animal
models (40) and some human clinical trials (41,42). IC
is mediated through reperfusion injury survival ki-
nase (RISK) and survivor-activating factor enhance-
ment (SAFE) pathways, which are complex but have
been well described (43). A number of cell surface G
protein-coupled receptors (44) initiate these survival
cascades utilizing intracellular signaling molecules
including phosphoinositol-3 kinase (PI3K), Akt,
p70s6k, p38MAPK, and ERK1/2. These pathways
converge upon the mitochondrial K-ATP channel(mK-ATP) (45,46), the ﬁnal common step in condi-
tioning pathways that inhibits the opening of the
mitochondrial permeability transition pore (mPTP),
preventing mitochondrial electrochemical uncou-
pling, loss of the membrane potential, depletion of
ATP, release of cytochrome C, hypercalcemia, and
ultimately, cell death (47,48).
Evidence that GLP-1 may activate IC mechanisms
has accumulated (49). GLP-1 is known to activate the
PI3K-Akt pathway in the pancreas (50), and GLP-1-
mediated cardioprotection in an isolated rat heart
model was associated with the RISK pathway. Inhi-
bition of p70s6 kinase, a downstream target of PI3K,
inhibited the cardioprotective effect of GLP-1.
Although PI3K and Akt are consistently involved in
GLP-1 cardioprotection (12,17), phosphorylation of
ERK1/2 occurred in some studies (13) but not others
(51). Pigs exposed to IR injury had reduced infarct size
when pretreated with exenatide. Levels of phos-
phorylated Akt and Bcl-2 were elevated after treat-
ment with exenatide, suggesting activation of
conditioning pathways (24).
The role of the GLP-1R in the activation of these
subcellular signaling pathways is unclear, with incon-
sistent evidence in animal models. In the glucose-
dependent rat model discussed above, the protective
effect of DPP-4 inhibition was lost by blocking the
GLP-1 receptor (35). However, GLP-1R knockout mice
still experienced cardioprotection with GLP-1 (16).
Recently, mice with cardiomyocyte-speciﬁc disrup-
tion of GLP-1R were shown to still experience robust
protection from liraglutide (25). Recent evidence
suggests that the GLP-1R may not be present in ven-
tricular cardiomyocytes at all (10). Either another
as-yet-unidentiﬁed receptor is mediating the GLP-1
effect on the RISK pathway of the cardiomyocyte or
indirect activation is occurring, with GLP-1 binding
a remote GLP-1R on endothelial or smooth muscle
cells that triggers paracrine release of cardioprotective
agents that act on the adjacent cardiomyocyte.
Activation of IC is associated with adenosine
signaling pathways (52,53). Recent work in anes-
thetized dogs showed that allogliptin-induced car-
dioprotection was abolished with blockade of
adenosine A1 receptor despite continued activation of
RISK pathways, suggesting an interaction between
adenosine and GLP-1 signaling and cardioprotective
“redundancy” (51). A simpliﬁed subcellular signaling
pathway through which GLP-1 may act to effect car-
dioprotection is proposed in Figure 2.
Some actions of GLP-1 have been shown to be
dependent upon the mK-ATP channel. This includes
concentration-dependent relaxation of rat aorta,
which was inhibited by the mK-ATP blocking agent
FIGURE 2 Proposed Schema for GLP-1 Activation of Ischemic Conditioning Pathways
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GLP-1 binds to the GLP-1 receptor and activates the PI3K-Akt complex, which is part of the RISK pathway. This complex activates a cascade that
opens the mK-ATP channel. Opening of mK-ATP prevents opening of the mPTP during reperfusion, part of the ﬁnal common pathway of cell
death. Activation of PI3-Akt has also been associated with changes in transcription and translation promoting cell survival. Alternative re-
ceptors, or activation of pro-survival pathways without binding the GLP-1 receptor, may explain myocardial cardioprotection, despite the
purported absence of the GLP-1 receptor in recent studies. GLP-1R ¼ GLP-1 receptor; GLP-1RA ¼ GLP-1 receptor agonist; mPTP ¼mitochondrial
permeability transition pore.
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271glibenclamide (Diabeta, Sanoﬁ, Guildford, Surrey,
United Kingdom) (54). Glibenclamide also inhibited
ﬂow-mediated dilatation of human arteries in fore-
arm blood ﬂow studies with GLP-1 (55).
VASODILATORY AND HEMODYNAMIC EFFECTS. Reduc-
tion in systemic vascular resistance decreases after-
load, and venodilation reduces preload, both reduce
cardiac work and increase myocardial resistance to
ischemia, as does reduction in heart rate. Coronary
vasodilation also reduces ischemia by augmenting
blood supply and aiding collateral recruitment to the
myocardium.
GLP-1 produces vasodilation and microvascular
recruitment in animal models (56,57). Murine studies
show that GLP-1 vasodilates constricted coronary ar-
teries by increasing nitric oxide (NO)-mediated cGMP
release in smooth muscle cells. This is associated withreduced IR injury. Vasodilation was present in GLP-1R
knockout mice, suggesting it was a receptor-
independent effect. Vasodilation occurred with the
cleavage product GLP-1-(9-36) amide but not
with the GLP-1RA Exendin-4 (16). GLP-1-mediated
concentration-dependent relaxation of ex vivo rat
aorta was eliminated when K-ATP channels were
blocked, linking the hemodynamic effects of GLP-1 to
conditioning pathways as discussed above (54).
Research involving healthy human volunteers
demonstrated that GLP-1 infusion caused recruitment
of microvasculature in cardiac muscle assessed with
myocardial contrast echocardiography (58).
Studies examining the impact of GLP-1 on heart
rate and blood pressure have been limited to
GLP-1RA. Liraglutide reduced diastolic and systolic
blood pressure in mice by binding the GLP-1R, an
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272effect that was lost in GLP-1R knockout mice and was
mediated by atrial natriuretic peptide (ANP) (11). In
humans with diabetes mellitus, administration of
liraglutide did not result in an increase in ANP,
although it was associated with a small and possibly
detrimental rise in heart rate (59). A recent meta-
analysis including unpublished data from pharma-
ceutical companies suggested that GLP-1RA are asso-
ciated with a rise in heart rate (60). Liraglutide also
produced an elevated heart rate in an open label trial
of patients comparing it to sitagliptin in type 2 di-
abetics. Sitagliptin was not associated with a heart
rate rise suggesting that native GLP-1 may not have the
same effect or perhaps implicating the cleavage prod-
uct of GLP-1 in the hemodynamic effects of GLP-1 (61).
CHALLENGE OF UNDERSTANDING THE MECHANISM
OF GLP-1 CARDIOPROTECTION. A clear under-
standing of the mechanism by which GLP-1 elicits
cardioprotection has proved elusive. Differences be-
tween animal models make studies difﬁcult to
compare. It is not clear whether murine models are
reﬂective of larger mammals. The relationship be-
tween animal and human physiology, particularly
with regard to the location and presence of the GLP-1
receptor, mean that ﬁrm conclusions are difﬁcult to
draw. Even within published studies there is vari-
ability in cardioprotective potency largely attribut-
able to differences in study design.
Physiological studies in humans, although often
harder to perform and limited by ethical and practical
considerations, may provide clarity over the mecha-
nism by which GLP-1 exerts its cardioprotective effect.
Particular importance should be placed on limiting the
confounders implicit in human studies (such as med-
ications, diabetic status, comorbidities, and counter-
regulatory hormones) to ensure that useful informa-
tion can be gleaned. Where these factors cannot be
controlled, allowance should be made in discussion of
results. Areas of useful endeavor may include assess-
ment of the effects of GLP-1 in the human coronary
microcirculation and the interaction of RISK/SAFE
pathways with GLP-1. GLP-1 may act through multiple
pathways of protection, including some not yet
described, increasing its potential usefulness but also
the complexity of understanding its mechanism.
CLINICAL EVIDENCE OF
GLP-1-MEDIATED CARDIOPROTECTION
GLP-1-mediated cardioprotection is conserved in a
number of animal species including humans. The
evolutionary reason for this cardioprotection is
speculative. It may simply be conserved by associa-
tion with IC-mediated cardioprotection and this mayconfer a survival advantage by limiting birth-induced
fetal ischemia. Similarly, GLP-1-mediated protection
may have evolved to protect our prehistoric ancestors
when eating, the immobility that ensues may have
increased their vulnerability to predators. Whatever
the reason, it now provides a target, which may be
exploited for clinical beneﬁt, particularly in the
setting of cardiac ischemia.
A number of human studies have shown evidence
of GLP-1-mediated cardioprotection. These are sum-
marized in Table 1. Protection may limit nonlethal
forms of IR injury such as myocardial stunning or
post-infarct remodeling. Endpoints in clinical studies
have focused more heavily on these forms of IR
injury. Future clinical trials during elective or emer-
gent percutaneous coronary revascularization offer
an ethically acceptable method of assessing GLP-1
protection from lethal IR-injury.
GLP-1 has been shown to protect against ischemic
left ventricular dysfunction following periods of de-
mand ischemia induced with dobutamine stress
echocardiography (62). This effect has recently been
shown to be maintained even during a hyperglyce-
mic, hyperinsulinemic clamp, negating the role of
insulin in the cardioprotection observed (63). Similar
beneﬁt has been derived through the administration
of the DPP-4 inhibitor sitagliptin in both diabetic and
nondiabetic patients (64,65).
GLP-1 protects against cumulative myocardial
stunning following coronary balloon occlusion during
elective PCI, when assessed through the use of a left
ventricular conductance catheter (38,66). The pro-
tection is present whether GLP-1 is administered prior
to or after supply ischemia. This contrasts with IC,
which does not protect the ventricle against stunning
in the same manner (67). Protection from myocardial
stunning may have particular beneﬁt in those
patients with cardiogenic shock where ischemic con-
tractile dysfunction adds to the cascade of hemody-
namic failure associated with the condition. A 72-h
infusion of GLP-1 initiated following AMI produced
improvements in global and regional wall motion
on echocardiography (68). Myocardial stunning is
reversible, and the mechanisms underlying this
protection are almost certainly different to those
underlying infarction (69).
Patients treated with exenatide during ST-segment
elevation myocardial infarction (STEMI) had reduced
infarct size by 15% on cardiac magnetic resonance
imaging, although it failed to alter peak troponin
levels or left ventricular ejection fraction assessed at
90 days (70). Of note, all the beneﬁt seen in that study
occurred in patients with short ischemic times (71).
Further study of 58 primary PCI patients treated with
TABLE 1 Human Studies of GLP-1 or GLP-1RA-Mediated Cardioprotection
First Author (Ref. #) Year
Cardioprotective
Agent N Protocol Result
Nikolaidis et al. (82) 2004 GLP-1 21 72-hGLP-1 infusion initiated within 4 h of PPCI
in patients with severely impaired LV
function vs. saline control
Improved global and regional left ventricular
function on echocardiography
Sokos et al. (68) 2006 GLP-1 21 Subcutaneous infusion of GLP-1 given for 5
weeks in patients with NYHA functional
class III/IV heart failure vs. saline control
Improved quality of life score, 6-min walk
tests and left ventricular ejection fraction
Read et al. (64) 2010 Sitagliptin 14 Patients with coronary artery disease given
single dose of sitagliptin / placebo followed
by dobutamine stress echocardiogram.
Patients acted as their own control.
Sitagliptin improves ejection fraction and
regional tissue Doppler indices at peak
stress and 30-min recovery
Read et al. (66) 2011 GLP-1 20 GLP-1/saline infusion initiated after coronary
balloon occlusion in patients undergoing
PCI with further balloon occlusion at 30 min
GLP-1 infusion protects against stunning and
cumulative ischemic dysfunction on
pressure-volume loop measurement
Read et al. (62) 2012 GLP-1 14 Patients with coronary artery disease given
infusion of GLP-1 / placebo followed by
dobutamine stress echocardiogram.
Patients acted as their own control.
GLP-1 infusion improves ejection fraction and
regional tissue Doppler indices at peak
stress and 30-min recovery
Lonborg et al. (70) 2012 Exenatide 172 GLP-1 infusion initiated 15 min before
intervention in PPCI patients and continued
for 6 h
Reduced ﬁnal infarct size on CMR. No change
in biomarker rise or overall left ventricular
ejection fraction. No difference in clinical
outcome.
Woo et al. (72) 2013 Exenatide 58 Twice daily subcutaneous exenatide injection
for 72-h compared to placebo in patients
receiving PPCI
Reduced infarct size on CMR and reduced
biomarker rise (CK-MB and troponin-I)
McCormick et al. (65) 2014 Sitagliptin 20 Diabetic patients with coronary disease
underwent dobutamine stress
echocardiogram after 4 weeks of sitagliptin
Sitagliptin improves ejection fraction and
regional tissue Doppler indices at peak
stress and 30-min recovery compared to
baseline stress echocardiogram
McCormick et al. (38) 2015 GLP-1 20 GLP-1/saline infusion initiated prior to coronary
balloon occlusion in patients undergoing
PCI, monitored with pressure-volume loops
GLP-1 infusion protects against ischemic
dysfunction and myocardial stunning
when given prior to coronary balloon
occlusion
McCormick et al. (63) 2015 GLP-1 10 GLP-1 infusion given during dobutamine stress
echocardiogram, concurrently with
hyperglycemic, hyperinsulinemic clamp in
type 2 diabetic patients, who acted as their
own control
GLP-1 infusion improves ejection fraction and
regional tissue Doppler indices at peak
stress and 30-min recovery
Roos et al. (73) 2015 Exenatide 91 GLP-1 infusion initiated immediately before
PPCI and continued for 72 h
No change in ﬁnal infarct size, ejection
fraction or biomarker rise
CK-MB ¼ creatine kinase-MB; CMR ¼ cardiac magnetic resonance; GLP-1 ¼ glucagon-like peptide 1-(7-36) amide; GLP-1RA ¼ GLP-1 receptor agonist; LV ¼ left ventricular; PCI ¼ percutaneous coronary
intervention; PPCI ¼ primary percutaneous coronary intervention.
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273exenatide prior to reperfusion showed a reduction in
infarct size (on cardiac magnetic resonance imaging
and biomarker measurements) as well as improve-
ment in left ventricular systolic function at 6 months’
follow-up (72). In contrast, early results of the EXAMI
(Effect of additional treatment with Exenatide in
patients with an Acute Myocardial Infarction) trial
have shown no beneﬁt (on cardiac magnetic reso-
nance imaging infarct size or biomarkers) from a 72-h
exenatide infusion initiated prior to primary PCI for
STEMI (73).
GLP-1 has been administered in patients undergo-
ing coronary artery bypass graft. Although it did not
result in signiﬁcant differences in left ventricular
dysfunction, as assessed on echocardiography, there
was an overall reduction in the need for inotropes and
vasoactive infusions compared to controls (74). That
study also highlighted a reduction in ventriculararrhythmia, a surrogate for ischemia. A further
double-blind trial of GLP-1 infusion during on-pump
cardiac surgery resulted in improved glycemic con-
trol. No assessment of whether this intervention also
had a cardioprotective effect was reported (75).
Large-scale studies of DPP-4 inhibitors (SAVOR–
TIMI 53 [Saxagliptin Assessment of Vascular Out-
comes Recorded in patients with diabetes mellitus-
Thrombolysis In Myocardial Infarction 53], TECOS
[Trial Evaluating Cardiovascular Outcomes with
Sitagliptin], and EXAMINE [Examination of Cardio-
vascular Outcomes with Alogliptin versus Standard of
Care]) have demonstrated their cardiovascular safety
in diabetic patients. The primary endpoints of those
studies were cardiac events following long-term
therapy. Despite large numbers, those studies were
not designed to assess possible cardioprotection
during an acute ischemic event (76–78).
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274Cardiovascular outcome trials for GLP-RAs have not
yet been published, although the EXSCEL (Exenatide
Study of Cardiovascular Event-Lowering Trial;
NCT01144338) trial is due to ﬁnish in 2018. The
LEADER (Liraglutide Effect and Action in Diabetes:
Evaluation of Cardiovascular Outcome Results;
NCT01179048) study recently conﬁrmed a statistically
signiﬁcant reduction in major adverse cardiovascular
events when administering liraglutide to type 2 dia-
betic patients with a high cardiovascular risk (79)
indicating a cardioprotective effect, whereas the
FIGHT (Functional Impact of GLP-1 for Heart Failure
Treatment; NCT01800968) trial presented at the AHA
annual meeting in 2015 showed that liraglutide did
not negatively affect outcomes when administered to
patients with advanced heart failure (80). Whether
these trials are informative regarding the role of GLP-
1 in cardioprotection will depend upon further anal-
ysis of published data. This analysis may determine
the subgroup of patients who will derive clinical
beneﬁt from GLP-RAs.
Presently there are a number of clinical trials
looking to exploit the potential cardioprotective
beneﬁts of GLP-1 and GLP-1RA. The GOLD-PCI (GLP-1
Loading During Percutaneous Coronary Intervention;
NCT02127996) trial is a study investigating the effect
of GLP-1 infusion during elective PCI, whereas
COMBAT-MI (Combination Therapy in Myocardial
Infarction; NCT02404376) is examining the combi-
nation of IC and exenatide in patients with STEMI.
Trials such as these will provide further evidence
as to whether GLP-1 can move from a promising
molecule on the bench to a useful treatment in the
catheter laboratory.
TRANSLATION TO CLINICAL PRACTICE:
PROSPECTS AND CHALLENGES
The challenges of translating animal studies or small-
scale human physiological studies to large-scale
clinical trials of cardioprotection and from there tomainstream clinical practice are signiﬁcant. The ho-
mogenous nature of animal studies, or even highly
selected individuals in physiological studies, are
often not replicated in larger real world populations
where comorbidities and heterogeneity abrogate the
therapeutic effect.
At the heart of many problems of translation is a
failure to link understanding of mechanism to design
of the clinical trial (81). In the case of GLP-1, insights
into its place within pathways of cardioprotection will
improve understanding of how it might deliver most
beneﬁt. For example, if the primary basis of GLP-1
cardioprotection is IC then timing of therapy will be
crucial to the success of the intervention —too late
and the window for cardioprotection is closed.
Alternatively, a change in cardiovascular hemody-
namics may point trials towards endpoints around
cardiogenic shock.
Appropriate application of cardioprotection to a
well-deﬁned, large population at risk of signiﬁcant IR
injury with assessment of appropriate, unambiguous
endpoints (infarct size, arrhythmia burden, left ven-
tricular function, heart failure) will help provide
clarity as to the therapeutic potential of GLP-1 and its
derivatives.
CONCLUSIONS
GLP-1 is a promising option for the treatment of IR
injury. By accessing multiple cellular pathways it may
succeed where other agents have failed. Clearly well-
designed human studies of both the mechanisms and
beneﬁts of this cardioprotection are needed to eval-
uate GLP-1 as a cardioprotective agent and the pop-
ulation in which it will be most effective.
REPRINT REQUESTS AND CORRESPONDENCE: Dr.
Stephen P. Hoole, Papworth Hospital, Department
of Interventional Cardiology, Lakeside Crescent, Pap-
worth Everard, Cambridge, Cambs CB23 3RE, United
Kingdom. E-mail: stephen.hoole@papworth.nhs.uk.RE F E RENCE S1. Frohlich GM, Meier P, White SK, Yellon DM,
Hausenloy DJ. Myocardial reperfusion injury:
looking beyond primary PCI. Eur Heart J 2013;34:
1714–22.
2. Hausenloy DJ, Yellon DM. Myocardial ischemia-
reperfusion injury: a neglected therapeutic target.
J Clin Invest 2013;123:92–100.
3. Depre C, Vanoverschelde JL, Taegtmeyer H.
Glucose for the heart. Circulation 1999;99:
578–88.
4. Mortensen K, Christensen LL, Holst JJ,
Orskov C. GLP-1 and GIP are colocalized in a subsetof endocrine cells in the small intestine. Regul
Pept 2003:189–96.
5. Herrmann C, Goke R, Richter G, Fehmann HC,
Arnold R, Goke B. Glucagon-like peptide-1 and
glucose-dependent insulin-releasing polypeptide
plasma levels in response to nutrients. Digestion
1995;56:117–26.
6. Hausenloy DJ, Yellon DM. GLP-1 therapy:
beyond glucose control. Circ Heart Fail. United
States 2008:147–9.
7. Skoglund G, Hussain MA, Holz GG. Glucagon-
like peptide 1 stimulates insulin gene promoteractivity by protein kinase A-independent activa-
tion of the rat insulin I gene cAMP response
element. Diabetes 2000;49:1156–64.
8. Nauck MA, Niedereichholz U, Ettler R, et al.
Glucagon-like peptide 1 inhibition of gastric
emptying outweighs its insulinotropic effects
in healthy humans. Am J Physiol 1997;273:E981–8.
9. Holst JJ. The physiology of glucagon-like pep-
tide 1. Physiol Rev 2007;87:1409–39.
10. Pyke C, Heller RS, Kirk RK, et al. GLP-1 re-
ceptor localization in monkey and human tissue:
novel distribution revealed with extensively
J A C C : B A S I C T O T R A N S L A T I O N A L S C I E N C E V O L . 1 , N O . 4 , 2 0 1 6 Giblett et al.
J U N E 2 0 1 6 : 2 6 7 – 7 6 Glucagon-Like Peptide-1 and Cardioprotection
275validated monoclonal antibody. Endocrinology
2014;155:1280–90.
11. Kim M, Platt MJ, Shibasaki T, et al. GLP-1 re-
ceptor activation and Epac2 link atrial natriuretic
peptide secretion to control of blood pressure. Nat
Med. United States 2013:567–75.
12. Bose AK, Mocanu MM, Carr RD, Yellon DM.
Myocardial ischaemia-reperfusion injury is atten-
uated by intact glucagon like peptide-1 (GLP-1) in
the in vitro rat heart and may involve the p70s6K
pathway. Cardiovasc Drugs Ther 2007;21:253–6.
13. Ban K, Kim KH, Cho CK, et al. Glucagon-like
peptide (GLP)-1(9-36)amide-mediated cytopro-
tection is blocked by exendin(9-39) yet does not
require the known GLP-1 receptor. Endocrinology
2010;151:1520–31.
14. Deacon CF, Nauck MA, Toft-Nielsen M,
Pridal L, Willms B, Holst JJ. Both subcutaneously
and intravenously administered glucagon-like
peptide I are rapidly degraded from the NH2-
terminus in type II diabetic patients and in
healthy subjects. Diabetes 1995;44:1126–31.
15. Ravassa S, Zudaire A, Carr RD, Diez J. Anti-
apoptotic effects of GLP-1 in murine HL-1 car-
diomyocytes. Am J Physiol Heart Circ Physiol 2011;
300:H1361–72.
16. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS,
Drucker DJ, Husain M. Cardioprotective and vas-
odilatory actions of glucagon-like peptide 1 re-
ceptor are mediated through both glucagon-like
peptide 1 receptor-dependent and -independent
pathways. Circulation 2008;117:2340–50.
17. Bose AK, Mocanu MM, Carr RD, Brand CL,
Yellon DM. Glucagon-like peptide 1 can directly
protect the heart against ischemia/reperfusion
injury. Diabetes 2005;54:146–51.
18. Bose AK, Mocanu MM, Carr RD, Yellon DM.
Glucagon like peptide-1 is protective against
myocardial ischemia/reperfusion injury when given
either as a preconditioning mimetic or at reperfu-
sion in an isolated rat heart model. Cardiovasc
Drugs Ther 2005;19:9–11.
19. Nikolaidis LA, Elahi D, Hentosz T, et al. Re-
combinant glucagon-like peptide-1 increases
myocardial glucose uptake and improves left
ventricular performance in conscious dogs with
pacing-induced dilated cardiomyopathy. Circula-
tion 2004;110:955–61.
20. Nikolaidis LA, Doverspike A, Hentosz T, et al.
Glucagon-like peptide-1 limits myocardial stun-
ning following brief coronary occlusion and
reperfusion in conscious canines. J Pharmacol Exp
Ther 2005;312:303–8.
21. Bao W, Aravindhan K, Alsaid H, et al. Albiglu-
tide, a long lasting glucagon-like peptide-1
analog, protects the rat heart against ischemia/
reperfusion injury: evidence for improving cardiac
metabolic efﬁciency. PLoS One 2011:e23570.
22. Wohlfart P, Linz W, Hubschle T, et al. Car-
dioprotective effects of lixisenatide in rat
myocardial ischemia-reperfusion injury studies.
J Transl Med 2013;11:84.
23. Noyan-Ashraf MH, Momen MA, Ban K, et al.
GLP-1R agonist liraglutide activates cytopro-
tective pathways and improves outcomes afterexperimental myocardial infarction in mice. Dia-
betes 2009;58:975–83.
24. Timmers L, Henriques JP, de Kleijn DP, et al.
Exenatide reduces infarct size and improves car-
diac function in a porcine model of ischemia and
reperfusion injury. J Am Coll Cardiol 2009;53:
501–10.
25. Ussher JR, Baggio LL, Campbell JE, et al. Inacti-
vation of the cardiomyocyte glucagon-like peptide-1
receptor (GLP-1R) unmasks cardiomyocyte-
independent GLP-1R-mediated cardioprotection.
Mol Metab 2014:507–17.
26. Lopaschuk GD, Saddik M. The relative contri-
bution of glucose and fatty acids to ATP produc-
tion in hearts reperfused following ischemia. Mol
Cell Biochem 1992;116:111–6.
27. Taegtmeyer H. Energy metabolism of the
heart: from basic concepts to clinical applications.
Curr Probl Cardiol 1994;19:59–113.
28. Sun D, Nguyen N, DeGrado TR, Schwaiger M,
Brosius FC, 3rd. Ischemia induces translocation of
the insulin-responsive glucose transporter GLUT4
to the plasma membrane of cardiac myocytes.
Circulation 1994;89:793–8.
29. Kloner RA, Nesto RW. Glucose-insulin-potas-
sium for acute myocardial infarction: continuing
controversy over cardioprotection. Circulation
2008;117:2523–33.
30. Selker HP, Beshansky JR, Sheehan PR, et al.
Out-of-hospital administration of intravenous
glucose-insulin-potassium in patients with sus-
pected acute coronary syndromes: the IMMEDIATE
randomized controlled trial. JAMA. United States
2012:1925–33.
31. Myat A, Redwood SR, Gersh BJ, Yellon DM,
Marber MS. Diabetes, incretin hormones and car-
dioprotection. Heart 2014;100:1550–61.
32. Luptak I, Yan J, Cui L, Jain M, Liao R, Tian R.
Long-term effects of increased glucose entry on
mouse hearts during normal aging and ischemic
stress. Circulation 2007:901–9.
33. Nikolaidis LA, Elahi D, Shen YT, Shannon RP.
Active metabolite of GLP-1 mediates myocardial
glucose uptake and improves left ventricular per-
formance in conscious dogs with dilated cardio-
myopathy. Am J Physiol Heart Circ Physiol 2005;
289:H2401–8.
34. Kavianipour M, Ehlers MR, Malmberg K, et al.
Glucagon-like peptide-1 (7-36) amide prevents the
accumulation of pyruvate and lactate in the
ischemic and non-ischemic porcine myocardium.
Peptides 2003:569–78.
35. Hausenloy DJ, Whittington HJ, Wynne AM,
et al. Dipeptidyl peptidase-4 inhibitors and GLP-1
reduce myocardial infarct size in a glucose-
dependent manner. Cardiovasc Diabetol 2013;12:
154.
36. Aravindhan K, Bao W, Harpel MR, Willette RN,
Lepore JJ, Jucker BM. Cardioprotection resulting
from glucagon-like peptide-1 administration in-
volves shifting metabolic substrate utilization to
increase energy efﬁciency in the rat heart. PLoS
One 2015;10:e0130894.
37. Halbirk M, Norrelund H, Moller N, et al. Car-
diovascular and metabolic effects of 48-h
glucagon-like peptide-1 infusion in compensatedchronic patients with heart failure. Am J Physiol
Heart Circ Physiol 2010:H1096–102.
38. McCormick LM, Hoole SP, White PA, et al. Pre-
treatment with glucagon-like Peptide-1 protects
against ischemic left ventricular dysfunction and
stunning without a detected difference in
myocardial substrate utilization. J Am Coll Cardiol
Intv 2015;8:292–301.
39. Gejl M, Lerche S, Mengel A, et al. Inﬂuence of
GLP-1 on myocardial glucose metabolism in
healthy men during normo- or hypoglycemia.
PLoS One 2014;9:e83758.
40. Murry CE, Jennings RB, Reimer KA. Pre-
conditioning with ischemia: a delay of lethal cell
injury in ischemic myocardium. Circulation 1986;
74:1124–36.
41. Hoole SP, Heck PM, Sharples L, et al. Cardiac
Remote Ischemic Preconditioning in Coronary
Stenting (CRISP Stent) Study: a prospective, ran-
domized control trial. Circulation 2009;119:820–7.
42. Davies WR, Brown AJ, Watson W, et al.
Remote ischemic preconditioning improves
outcome at 6 years after elective percutaneous
coronary intervention: the CRISP stent trial long-
term follow-up. Circ Cardiovasc Interv 2013;6:
246–51.
43. Hausenloy DJ, Tsang A, Yellon DM. The
reperfusion injury salvage kinase pathway: a
common target for both ischemic preconditioning
and postconditioning. Trends Cardiovasc Med
2005;15:69–75.
44. Kin H, Zatta AJ, Lofye MT, et al. Post-
conditioning reduces infarct size via adenosine
receptor activation by endogenous adenosine.
Cardiovasc Res 2005;67:124–33.
45. Garlid KD, Paucek P, Yarov-Yarovoy V, et al.
Cardioprotective effect of diazoxide and its inter-
action with mitochondrial ATP-sensitive Kþ
channels. Possible mechanism of cardioprotection.
Circ Res 1997;81:1072–82.
46. Kristiansen SB, Henning O, Kharbanda RK,
et al. Remote preconditioning reduces ischemic
injury in the explanted heart by a KATP channel-
dependent mechanism. Am J Physiol Heart Circ
Physiol 2005;288:H1252–6.
47. Hausenloy DJ, Ong SB, Yellon DM. The mito-
chondrial permeability transition pore as a target
for preconditioning and postconditioning. Basic
Res Cardiol 2009;104:189–202.
48. Hausenloy DJ, Duchen MR, Yellon DM. Inhib-
iting mitochondrial permeability transition pore
opening at reperfusion protects against ischaemia-
reperfusion injury. Cardiovasc Res 2003;60:
617–25.
49. Ravassa S, Zudaire A, Diez J. GLP-1 and car-
dioprotection: from bench to bedside. Cardiovasc
Res 2012;94:316–23.
50. Doyle ME, Egan JM. Mechanisms of action of
glucagon-like peptide 1 in the pancreas. Pharma-
col Ther 2007:546–93.
51. Ihara M, Asanuma H, Yamazaki S, et al. An
interaction between glucagon-like peptide-1 and
adenosine contributes to cardioprotection of a
dipeptidyl peptidase 4 inhibitor from myocardial
ischemia-reperfusion injury. Am J Physiol Heart
Circ Physiol 2015;308:H1287–97.
Giblett et al. J A C C : B A S I C T O T R A N S L A T I O N A L S C I E N C E V O L . 1 , N O . 4 , 2 0 1 6
Glucagon-Like Peptide-1 and Cardioprotection J U N E 2 0 1 6 : 2 6 7 – 7 6
27652. Krieg T, Qin Q, McIntosh EC, Cohen MV,
Downey JM. ACh and adenosine activate PI3-
kinase in rabbit hearts through transactivation of
receptor tyrosine kinases. Am J Physiol Heart Circ
Physiol 2002;283:H2322–30.
53. Kitakaze M, Hori M, Takashima S, Sato H,
Inoue M, Kamada T. Ischemic preconditioning in-
creases adenosine release and 5’-nucleotidase ac-
tivity during myocardial ischemia and reperfusion
in dogs. Implications for myocardial salvage. Cir-
culation 1993;87:208–15.
54. Green BD, Hand KV, Dougan JE,
McDonnell BM, Cassidy RS, Grieve DJ. GLP-1 and
related peptides cause concentration-dependent
relaxation of rat aorta through a pathway
involving KATP and cAMP. Arch Biochem Biophys
2008;478:136–42.
55. Basu A, Charkoudian N, Schrage W, Rizza RA,
Basu R, Joyner MJ. Beneﬁcial effects of GLP-1 on
endothelial function in humans: dampening by
glyburide but not by glimepiride. Am J Physiol
Endocrinol Metab 2007;293:E1289–95.
56. Dong Z, Chai W, Wang W, et al. Protein kinase
A mediates glucagon-like peptide 1-induced nitric
oxide production and muscle microvascular
recruitment. Am J Physiol Endocrinol Metab 2013;
304:E222–8.
57. Golpon HA, Puechner A, Welte T, Wichert PV,
Feddersen CO. Vasorelaxant effect of glucagon-
like peptide-(7-36)amide and amylin on the pul-
monary circulation of the rat. Regul Pept 2001;
102:81–6.
58. Subaran SC, Sauder MA, Chai W, et al. GLP-1 at
physiological concentrations recruits skeletal and
cardiac muscle microvasculature in healthy
humans. Clin Sci (Lond) 2014;127:163–70.
59. Lovshin JA, Barnie A, DeAlmeida A, Logan A,
Zinman B, Drucker DJ. Liraglutide promotes
natriuresis but does not increase circulating levels
of atrial natriuretic peptide in hypertensive sub-
jects with type 2 diabetes. Diabetes Care 2015;38:
132–9.
60. Robinson LE, Holt TA, Rees K, Randeva HS,
O’Hare JP. Effects of exenatide and liraglutide on
heart rate, blood pressure and body weight: sys-
tematic review and meta-analysis. BMJ Open
2013;3.
61. Pratley RE, Nauck M, Bailey T, et al. Liraglutide
versus sitagliptin for patients with type 2 dia-
betes who did not have adequate glycaemic
control with metformin: a 26-week, randomised,
parallel-group, open-label trial. Lancet 2010;375:
1447–56.
62. Read PA, Khan FZ, Dutka DP. Cardioprotection
against ischaemia induced by dobutamine stressusing glucagon-like peptide-1 in patients with
coronary artery disease. Heart 2012;98:408–13.
63. McCormick LM, Heck PM, Ring LS, et al.
Glucagon-like peptide-1 protects against ischemic
left ventricular dysfunction during hyperglycemia
in patients with coronary artery disease and type 2
diabetes mellitus. Cardiovasc Diabetol 2015;14:
102.
64. Read PA, Khan FZ, Heck PM, Hoole SP,
Dutka DP. DPP-4 inhibition by sitagliptin improves
the myocardial response to dobutamine stress and
mitigates stunning in a pilot study of patients with
coronary artery disease. Circ Cardiovasc Imaging
2010;3:195–201.
65. McCormick LM, Kydd AC, Read PA, et al.
Chronic dipeptidyl peptidase-4 inhibition with
sitagliptin is associated with sustained protection
against ischemic left ventricular dysfunction in a
pilot study of patients with type 2 diabetes mel-
litus and coronary artery disease. Circ Cardiovasc
Imaging 2014:274–81.
66. Read PA,Hoole SP,White PA, et al. A pilot study
to assess whether glucagon-like peptide-1 protects
the heart from ischemic dysfunction and attenuates
stunning after coronary balloon occlusion in
humans. Circ Cardiovasc Interv 2011;4:266–72.
67. Hoole SP, Khan SN, White PA, et al. Remote
ischaemic pre-conditioning does not attenuate
ischaemic left ventricular dysfunction in humans.
Eur J Heart Fail 2009;11:497–505.
68. Sokos GG, Nikolaidis LA, Mankad S, Elahi D,
Shannon RP. Glucagon-like peptide-1 infusion im-
proves left ventricular ejection fraction and func-
tional status in patients with chronic heart failure.
J Card Fail 2006;12:694–9.
69. Kloner RA, Jennings RB. Consequences of
brief ischemia: stunning, preconditioning, and
their clinical implications: part 1. Circulation 2001;
104:2981–9.
70. Lonborg J, Vejlstrup N, Kelbaek H, et al.
Exenatide reduces reperfusion injury in patients
with ST-segment elevation myocardial infarction.
Eur Heart J 2012;33:1491–9.
71. Lonborg J, Kelbaek H, Vejlstrup N, et al. Exe-
natide reduces ﬁnal infarct size in patients with
ST-segment-elevation myocardial infarction and
short-duration of ischemia. Circ Cardiovasc Interv
2012;5:288–95.
72. Woo JS, Kim W, Ha SJ, et al. Cardioprotective
effects of exenatide in patients with ST-segment-
elevation myocardial infarction undergoing pri-
mary percutaneous coronary intervention: results
of exenatide myocardial protection in revasculari-
zation study. Arterioscler Thromb Vasc Biol 2013;
33:2252–60.73. Roos S, Timmers L, van Hout G et al. Exenatide
Does Not Improve Myocardial Salvage in Patients
With An Acute Myocardial Infarction Successfully
Treated With Primary Percutaneous Coronary
Intervention: The First Results of the EXAMI Trial.
Presented at: TCT 2015. October 11-15, 2015; San
Francisco, CA.
74. Sokos GG, Bolukoglu H, German J, et al. Effect
of glucagon-like peptide-1 (GLP-1) on glycemic
control and left ventricular function in patients
undergoing coronary artery bypass grafting. Am J
Cardiol 2007;100:824–9.
75. Kohl BA, Hammond MS, Cucchiara AJ,
Ochroch EA. Intravenous GLP-1 (7-36) amide for
prevention of hyperglycemia during cardiac sur-
gery: a randomized, double-blind, placebo-
controlled study. J Cardiothorac Vasc Anesth
2014;28:618–25.
76. Scirica BM, Bhatt DL, Braunwald E, et al.
Saxagliptin and cardiovascular outcomes in pa-
tients with type 2 diabetes mellitus. N Engl J Med
2013;369:1317–26.
77. White WB, Cannon CP, Heller SR, et al. Alog-
liptin after acute coronary syndrome in patients
with type 2 diabetes. N Engl J Med 2013;369:
1327–35.
78. Green JB, Bethel MA, Armstrong PW, et al.
Effect of Sitagliptin on Cardiovascular Outcomes in
Type 2 Diabetes. N Engl J Med 2015;373:232–42.
79. NovoNordisk. Victoza signiﬁcantly reduces the
risk of major adverse cardiovascular events in the
LEADER trial. Available at: http://www.novonordisk.
com/bin/getPDF.1991879.pdf. Accessed March
2016.
80. Margulies K, Anstrom K, Redﬁeld M et al. A
randomized trial of liraglutide for high-risk heart
failure patients with reduced ejection fraction.
Presented at the Proceedings of the American
Heart Association Scientiﬁc Sessions. November
7-11, 2015; Orlando, FL.
81. Giblett JP, West NE, Hoole SP. Cardioprotec-
tion for percutaneous coronary intervention—
reperfusion quality as well as quantity. Int J Cardiol
2014;177:786–93.
82. Nikolaidis LA, Mankad S, Sokos GG, et al. Ef-
fects of glucagon-like peptide-1 in patients with
acute myocardial infarction and left ventricular
dysfunction after successful reperfusion. Circula-
tion 2004;109:962–5.KEY WORDS GLP-1, glucagon-like
peptide-1, ischemia reperfusion injury,
ischemic heart disease, percutaneous
coronary intervention
